GFAP and Alexander disease: Furthermore, since CSPGs also affect neural development, with low expression during the embryonic and early postnatal stages and gradually increasing with age [43], accompanied by a decline in neural plasticity, the overexpression of CSPGs by GFAP‐mutant astrocytes may contribute to early‐onset symptoms in AxD patients.